Automated and sensitive method for the determination of formoterol in human plasma by high-performance liquid chromatography and electrochemical detection

Campestrini, Joelle; Lecaillon, J. B.; Godbillon, J.

doi:10.1016/s0378-4347(97)00425-8

Cited by 25 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is possible that formoterol also modulates adhesion molecule upregulation at this level on fibroblasts. Formoterol has been detected in plasma samples at a concentration of 2.5610 -10 M 1 h after inhalation of a 120-mg dose [40], which is six times higher than a conventional dose. No results are available regarding concentrations reached in lung tissue, but locally higher concentrations may very well be present after regular inhaled doses.…”

Section: ±10mentioning

confidence: 89%

Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts

Spoelstra¹,

Postma²,

Hovenga³

et al. 2000

Eur Respir J

View full text Add to dashboard Cite

The glucocorticoid budesonide and the long-acting b 2 -adrenoceptor agonist formoterol are used in asthma therapy for their anti-inflammatory and bronchodilating effects, respectively. Since expression of adhesion molecules on resident cells in the lung plays an important role in asthmatic inflammatory responses, the effects of these drugs on the cytokine-induced intercellular adhesion molecule-1 (ICAM)-1 and vascular cell adhesion molecule-1 (VCAM)-1 expression of human lung fibroblasts were investigated.Budesonide and formoterol were added in the absence or presence of interleukin (IL)-1b, tumour necrosis factor-a (TNF-a), interferon gamma (IFN-c) or IL-4 to human lung fibroblasts; ICAM-1 and VCAM-1 expression were measured after 8 h using a cell surface enzyme linked immunosorbent assay (ELISA).It was found that both budesonide and formoterol significantly inhibited (p<0.05) the increased expression of ICAM-1 and VCAM-1 after stimulation with IL-1b (maximal inhibition (median (25±75% percentiles) 50 (48±52) and 61% (42±69), respectively, with budesonide and 55 (50±73) and 86% (64±94), respectively, with formoterol (10 -7 M)), TNF-a (maximal inhibition 49 (46±57) and 57% (44±68), respectively, with budesonide and 44 (40±75) and 62% (52±83) respectively, with formoterol), IFN-c (maximal inhibition 64% (41±67) with budesonide and 39% (29±49) with formoterol for ICAM-1) and IL-4 (maximal inhibition 82% (69±92) with budesonide and 43% (33±67) with formoterol for VCAM-1) in a dose-dependent manner.The results show that budesonide, as well as formoterol, in probably clinically relevant concentrations inhibits cytokine-induced adhesion molecule expression on human lung fibroblasts from a concentration of 10 -9 M. This inhibitory effect on resident cells may have implications for the infiltration of inflammatory cells into pulmonary tissue during therapy with these drugs in asthma. Eur Respir J 2000; 15: 68±74.

show abstract

Section: ±10mentioning

confidence: 89%

Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts

Spoelstra¹,

Postma²,

Hovenga³

et al. 2000

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…The determination of Formoterol in human serum and plasma required a very sensitive method due to the fact that only very low concentrations were available for analysis. After the application of 120 g (inhaled) Formoterol, the maximum concentration value (C max ) was about 80 pg/mL [1]. For some studies much lower dosages down to 9 g should be applied and the pharmacokinetic profile should be monitored.…”

Section: Introductionmentioning

confidence: 99%

“…All published methods regarding Formoterol related substances have a LLOQ between 50 pg/mL and 5 ng/mL in plasma or urine except Formoterol itself for which a LLOQ from 4 to 20 pg/mL was achieved with very time consuming methods [1,2]. The approach used by the authors is a combination of specific sample preparation on an ion exchange pre column (SCX 3) and a very sensitive HPLC-MS/MS system (API 4000).…”

Section: Introductionmentioning

confidence: 99%

Ultra-sensitive determination of Formoterol in human serum by high performance liquid chromatography and electrospray tandem mass spectrometry

Mascher

Zech

Nave

et al. 2006

Journal of Chromatography B

View full text Add to dashboard Cite

“…Campestrini et al reported that the plasma concentration of formoterol reached approximately 300 pM after inhalation of 90 mg of formoterol. 63 Gravett et al speculated that the local concentration of formoterol is approximately 10 nM (assuming a maximal single dose of 24 mg, lung deposition of 18.6%, and a tidal volume of 500 ml). 26 Although the actual concentration in the airway is more difficult to ascertain, the concentration of more than 1 mM in the inflammation cites seems to be hard to achieve after formoterol treatment during asthma attack.…”

Section: Discussionmentioning

confidence: 99%

Effect of beta2-adrenergic agonists on eosinophil adhesion, superoxide anion generation, and degranulation

Noguchi

Nakagome

Kobayashi

et al. 2015

Allergology International

View full text Add to dashboard Cite

show abstract

Automated and sensitive method for the determination of formoterol in human plasma by high-performance liquid chromatography and electrochemical detection

Cited by 25 publications

References 7 publications

Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts

Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts

Ultra-sensitive determination of Formoterol in human serum by high performance liquid chromatography and electrospray tandem mass spectrometry

Effect of beta2-adrenergic agonists on eosinophil adhesion, superoxide anion generation, and degranulation

Contact Info

Product

Resources

About